AT-1002 TFA
目录号 : GC34477
AT-1002TFA是一种6聚体合成肽，是一种紧密连接(junction)的调节剂和吸收增强剂。
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
AT-1002 TFA, a 6-mer synthetic peptide[1], is a tight junction regulator and absorption enhancer[2].
AT-1002, a 6-mer synthetic peptide, belongs to an emerging novel class of compounds that reversibly increase paracellular transport of molecules across the epithelial barrier. AT-1002 can undergo Cys-Cys dimerization[1].Undifferentiated Caco-2 cells are treated with AT-1002 (0 to 5 mg/mL, 3 or 24 hours) and viability is assessed by measuring cellular ATP content. Treatment with AT-1002 for up to 3 h does not affect cell viability at any concentration. In particular, the viability of Caco-2 cells is not affected by 5 mg/mL AT-1002. AT-1002 reduces cell viability after 24 h at concentrations of 2.5 mg/mL and higher. However, the cells remain viable after 24 h if the cells are washed after exposure to AT-1002 for 3 h indicating that AT-1002 does not irreversibly damage cells[2]. Cell Viability Assay[2] Cell Line: Caco-2 cells
[1]. Li M, et al. Structure-activity relationship studies of permeability modulating peptide AT-1002. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4584-6. [2]. Gopalakrishnan S, et al. Mechanism of action of ZOT-derived peptide AT-1002, a tight junction regulator and absorption enhancer. Int J Pharm. 2009 Jan 5;365(1-2):121-30.
| Cas No. | SDF | ||
| Canonical SMILES | N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CS)C(N[C@@H]([C@H](CC)C)C(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(O)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O | ||
| 分子式 | C34H54F3N9O9S | 分子量 | 821.91 |
| 溶解度 | DMSO : 33.33 mg/mL (40.55 mM; Need ultrasonic); H2O : 1 mg/mL (1.22 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2167 mL | 6.0834 mL | 12.1668 mL |
| 5 mM | 0.2433 mL | 1.2167 mL | 2.4334 mL |
| 10 mM | 0.1217 mL | 0.6083 mL | 1.2167 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。